Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older

Peter J Collignon
Med J Aust 2014; 201 (4): . || doi: 10.5694/mja14.00272
Published online: 18 August 2014

To the Editor: Menzies and colleagues promote the 23-valent polysaccharide pneumococcal vaccine (23vPPV) as effective in people aged 65 years or older.1 I believe their data show exactly the opposite. The vaccine appears to be ineffective.

  • Medical School, Australian National University, Canberra, ACT.


Competing interests:

No relevant disclosures.

  • 1. Menzies RI, Jayasinghe SH, Krause VL, et al. Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older. Med J Aust 2014; 200: 112-115. <MJA full text>
  • 2. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1746.
  • 3. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease — United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005; 54: 893-897.
  • 4. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354: 1455-1463.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.